Cappella Medical Devices has announced the initial long term follow up data for its Sideguard coronary sidebranch stent from Manchester Royal Infirmary in the UK.

The stent was successfully implanted in 38 patients and showed no signs of peri-procedural complications, with MACE rates of 5.3% at the one-year follow-up.

The self-expanding nitinol stent features a proprietary split-sheath, balloon-released technology that ensures precise placement on the ostial borderline.

The Sideguard was developed to protect the ostium of the sidebranch in the treatment of bifurcation disease.

Previous results from the single centre clinical experience confirmed that preservation of the sidebranch of diseased coronary arteries by protecting the ostium has short and long-term benefits.